A new immune therapy for people with low IgG
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a new immunoglobulin treatment (V-Immune) for people with primary IgG deficiency who are already on IVIG therapy. It aims to see if this new therapy can effectively replace their current treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 2 years or older
- You have a primary IgG deficiency and are currently receiving IVIG therapy
- Your IgG levels have been at least 500 mg/dL in the past 90 days
- You have not had a severe allergic reaction to blood products or IgG
- You are not pregnant or planning to become pregnant
- You do not have active infections, certain heart or kidney problems, or other exclusions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an IV medicine called V-IMMUNE® for people with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The study aims to see if V-IMMUNE® can safely raise platelet counts in both children and adults.
This study tests an intravenous immunoglobulin (IVIG) treatment, which is a way of giving you antibodies to help fight infections. It aims to see if this treatment is safe and effective for people with certain immune deficiencies.
This study looks at whether a different dose of IVIg (antibody treatment through the vein) or adding antibiotics can help prevent infections in people with low antibody levels. It's for patients already on steady IVIg who cannot safely stop it.
This trial tests whether giving immunoglobulin to adults with low antibody levels can prevent infections. It aims to compare immunoglobulin with antibiotic therapy or no added treatment for people with blood conditions.
This study tests a new intravenous immunoglobulin (IVIG) treatment called KIg10 (QIVIGY) for people with chronic inflammatory demyelinating polyneuropathy (CIDP). It aims to see if this treatment can help manage symptoms and maintain stability.
This study looks at how well immunoglobulin replacement therapy works in people with low antibody levels and how it affects the immune system. It aims to help improve treatment for primary antibody immunodeficiencies.
Hear when a new Immunodeficiencies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.